Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Silence Therapeutics (SLN) FCF Margin: 2019-2024

Historic FCF Margin for Silence Therapeutics (SLN) over the last 6 years, with Dec 2024 value amounting to 156.85%.

  • Silence Therapeutics' FCF Margin fell 514355.00% to 6,857.23% in Q3 2025 from the same period last year, while for Sep 2025 it was 281.06%, marking a year-over-year decrease of 3472.00%. This contributed to the annual value of 156.85% for FY2024, which is 36.00% down from last year.
  • Silence Therapeutics' FCF Margin amounted to 156.85% in FY2024, which was down 0.23% from 156.49% recorded in FY2023.
  • In the past 5 years, Silence Therapeutics' FCF Margin registered a high of 44.26% during FY2021, and its lowest value of 264.22% during FY2022.
  • For the 3-year period, Silence Therapeutics' FCF Margin averaged around 192.52%, with its median value being 156.85% (2024).
  • As far as peak fluctuations go, Silence Therapeutics' FCF Margin tumbled by 96,519bps in 2020, and later surged by 30,535bps in 2021.
  • Silence Therapeutics' FCF Margin (MRY) stood at 261.09% in 2020, then skyrocketed by 117bps to 44.26% in 2021, then crashed by 697bps to 264.22% in 2022, then skyrocketed by 41bps to 156.49% in 2023, then decreased by 0bps to 156.85% in 2024.
  • Its FCF Margin stands at 156.85% for FY2024, versus 156.49% for FY2023 and 264.22% for FY2022.